• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    1. METHOD FOR OBTAINING 2,3,4-TRINOR-M-INTER-FENSHNG PROTAGLANDINE DERIVATIVES of the general formula j daoRi, CgO where R is alkyl with 1-4 carbon atoms, an alkali metal cation or a primary, secondary, tertiary or quaternary ammonium cation; R2, .HR independently of each other. are hydrogen, alkanoyl with 1-4 carbon atoms, tetrahydropyranyl, ethoxyethyl or trialkylsilyl group, where alkyl with 1-4 carbon atoms; R, hydrogen or alkyl with 1-4 carbon atoms; To a hexyl, heptyl, phenoxymethyl, m-trifluoromethylphenoxymethyl group or a group of the formula -CH-Rg I ° Z where Z is an amino group, an alkanoyl amino group with 1-4 carbon atoms, benzoylamino or thozi Rg is an alleino group, and a kil with 4-6 carbon atoms, 0) phenyl or benzyl, characterized in that the bicyclic lactol of the general formula UN g CgO where EL-RK have the indicated meanings, are reacted with a phosphorane obtained from the phosphonium salt of the 9-complete formula (III) I PH3P CHXxxX COHon where Ph is phenyl; X is a monovalent anion, under the action of a strong base in a dipolar aprotic solvent.
    公开号:SU1138020A3
    申请号:SU823424149
    申请日:1982-04-13
    公开日:1985-01-30
    发明作者:Секели Иштван；Кекеши Кристина；Ловас Марианн；Ботар Шандор；Хадхази Пал；Ракоци Иштван；Мусбек Ласло；Шкопал Юдит；Штадлер Иштван；Хорват Карой；Ковач Габор；Кермеци Петер
    申请人:Хиноин Дьедьсер Еш Ведьесети Термекек Дьяра Рт (Инопредприятие)；
    IPC主号:
    专利说明:

    derived derivative of general formula (IV)
    COORi
    Yoke
    K, O
    where R is hydrogen;
    R-- RC- has the indicated meanings converted to an ester derivative of the formula {IV), where R (is alkyl with 1-4 carbon atoms, and when Z is an unsubstituted amino group, is acylated to obtain a compound of formula (IV), where Z has other the indicated values, and the obtained compound of formula (IV) are treated with compound EX, where X is halogen, and E is a halogen or N-succinimide group, in an organic solvent which is not miscible with water or in a two-phase system obtained from it, if necessary in the presence of an acid acceptor,
    obtained halogenated PC1l derivative of general formula (V)
    COORi
    RjO have the indicated meanings, and Z has meanings other than hydrogen,
    is treated with a base followed by hydrolysis of a compound of formula (I), where RJ is alkyl, into a compound of formula (I), where hydrogen, or by salt formation of a compound of formula I, where hydrogen, into a compound of formula (I), where R is the specified cation, or deacylating a compound of formula (1), where Z is an alkanoyl amino group, to a compound of formula (I), where Z is an unsubstituted amino group.
    2. A method according to claim 1, characterized in that sodium bicarbonate is used as an acid acceptor when treating a compound of formula (IV) with compound X.
    3. A method according to claim 1, characterized in that the halogenated PGlg derivative of the general formula (V) is treated with 1,5-diazabicyclo (4.3.0) non-5-ene.
    The invention relates to a method for producing new prostaglandin derivatives having high anti-agglomeration activity with respect to thermobicites and high stability of S solutions. The known reaction of olefination of prostaglandin derivatives by the action on carbonyl derivatives of prostaglandins alkylidenephosphorane, obtained from the quaternary salts of phosphonium and strong bases in the dapolar aprotic solvent L. The purpose of the invention is to obtain new prostaglandin derivatives with a higher stability in solutions than their natural counterparts, while maintaining high biological activity, in particular antiaggregatory against platelet activity. The goal is achieved based on a known reaction method of producing 2,3,4-trinol-m-inter-phenylene prostaglandin derivatives of the general formula Cooiii where R is alkyl with 1-4 carbon atoms alkali metal cation or primary, secondary, tertiary or quaternary ammonium cation ; 3 R independently of one another are hydrogen, alkanoyl with 1-4 carbon atoms, tetrahydropyranyl, ethoxyethyl or trialkylsilyl group where alkyl with 1-4 carbon atoms; hydrogen or alkyl with 1-4 carbon atoms; R - is a hexyl, heptyl, phenoxymethyl, m-trifluoromethylphenoxymethyl group or a group of the formula -CH-R, I b; where Z is an amino group, an alkanoylamino group with 1-4 carbon atoms, a benzoylamino or zylamino group, and Rg is an alkane with 4-6 carbon atoms, phenyl or benzyl, which means that the bicyclic lactol of the general formula where these the value is reacted with a phosphorus obtained from the phosphonium salt of the general formula Soon where Ph is phenyl and X® is a monovalent anion, under the action of a strong base in a di polar aprotic solvent, the resulting derivative of the general formula RO where R is hydrogen. 204 Rj-R have the indicated meanings, are converted into an ester derivative of formula IV, and R, i is alkyl with 1-4 carbon atoms, and when L is an unsubstituted amino group, is acylated to obtain a compound of formula IV, where Z has the other indicated meanings and the resulting compound of formula IV is treated with compound EX, where X is halogen, and E is a halogen or N-succinimide group, in an organic solvent which is not miscible with water, or in a two-phase system obtained from it and water, if necessary in the presence of an acid acceptor, obtained halogenated e PGlj is a derivative of the general formula COORi where they have the indicated meanings, and Z has values other than hydrogen, is treated with a base followed by allocation of the target product or hydrolysis of a compound of formula (I), where R is alkyl, to a compound of formula (I), where hydrogen, or by salt formation of a compound of formula (I), where RJ is hydrogen, into a compound of formula (I), where RJ is a specified cation, or by deacylation of a compound of formula (I), where Z is an alkanoylamino group, into a compound of formula (I), where Z is unsubstituted amino group. It is preferable to use an acid bicarbonate compound as an acid acceptor for processing the compound of formula (IV). Treatment of the halogenated derivative of the general formula 1,5-diazabicyclo (4,3,0) non5-ene is preferred. The resulting derivatives of general formula (I), like natural PGTig, suppress platelet aggregation and can loosen the agglomerates formed. This activity was determined on platelet-rich plasma of humans and guinea pigs and compared with the known compound PGl sodium salt. Aggregation was caused by the addition of 4 μmol / ml adenosine diphosphate. The table shows the concentrations of the tested substances, not
    PGI Sodium Salt
    Sodium salt 5 (g) -2,3,4-trinor1, 5-inter-m-phenylene-20-metsh1-PC1
    5 (E) -2., 3,4-trinor-1-1,5-inter-m-phenylene-20-methyl-PC1 ..- natrkeva
    salt
    5 (2) -2,3,4-trinor-1,5-inter-m-phenylene-20-e-1-PC1. -Sodium salt
    . 5 (E) -2,3,4-trinor-1,5-inter-m-phenylene-20-ethyl-PC1l-sodium salt
    As follows from the table, the compound obtained by the proposed method is inferior to its natural counterpart. However, the stability of the compound of formula (I) in the solutions is by an order greater than the stability of the natural analog, which is in water at pH. 7 within 3 min loses half of its activity, whereas the half-life of compounds of formula (1) is at least 7 days.
    Example 1. 2,3,4,17,18,19,20-heptanor-1,5-inter-m-phenylene-11, 15-bis-tetrahydropyranoloxy-1b-phenoxy / PC125 methyl ester.
    250 mg (10.41 mmol) of sodium hydride are placed in a dry, threefold flask equipped with a mannitac stirrer and thermometer. The flask was flushed with nitrogen, then 5 ml of anhydrous dimethyl sulfoxide was poured. A slow flow of nitrogen is passed through the flask and a slight nitrogen overpressure is maintained in the flask using a mercury shutter. The temperature of the suspension is slowly raised to 60 ° C, while gassing is observed. After its termination (approximately 30 minutes), the mixture is heated to 70 ° C and stirred at this temperature for the next 30 minutes. Get a solution of dark gray color, which when
    walkable, for 50th (
    ) and
    100% (EC (dd) suppression of nrjiei-ation
    1.75
    12.5
    14
    28
    20
    45
     2.45 g (5.68 mmol) of m-carboxybenzyltriphenylLosphonyl chloride, dried under vacuum, are added. The resulting red solution is stirred at room temperature for 0.5 h and then mixed with the solution
    1.57 g (2.59 mmol) 3.3a, /, 4,5,6,6a ft-hexahydro-2, hydroxy-4y - (Z-tetrahydropyranyloxy-4-phenoxybutenyl) 5 (X-tetrahydropyranyloxy-2H- cyclopenta (c) furan in; 500 µl of anhydrous dimethyl sulfoxide. The reaction mixture is stirred at 60 ° C for 1 h, then a mixture of 20 g of ice and 50 ml of water is taken out. The solution is extracted with 2 times 10 ml of ether. 4-5 2N aqueous solution of sodium bisulfite. This aqueous phase is extracted 4 times with 20 ml of ether and 2 times with 20 ml of ethyl acetate. The combined organic phases are dried with sodium sulfate, filtered and the solvent is evaporated under reduced pressure. The resulting crude product (2.5 g) is dissolved in 20 ml of ether and an ether solution of diazomethane is added dropwise to it at 0 ° C with stirring. The mixture is added until the yellow color of the reaction mixture is obtained. methyl ether is analyzed by thin layer chromatography. The acid has Rf 0.52 (benzol dioxane: acetic acid
    acid 20: 10: 1, silica gel), methyl alcohol) has Rf 0.73 (in case the formation of methyl ester is not quantitative, ether solution of diazomethane is added again. Crude methyl ether. after ether stripping off, the silica gel column is chromatographed, eluent benzene: dioxane:.: acetic acid 20: 10: 1, collect the corresponding Rf 0.73 fraction and evaporate to obtain 1.426 g (70%) of the product.
    EXAMPLE 2 Methyl ether 2,3,4,17,18,19,20 heptanor-1,5-interm-phenylene-1b-phenoxy-P (; P2 (X.
    The procedure of Example 1 is followed with the difference that a solution of 350 mg (1.29 mmol) of 3.30 |, ft, 4,5,6,601, ft-hexahydro-2oxy-4 - (3- hydroxy-4-phenoxy-1-transbutenyl) -5-hydroxy-2H-cyclopenta (c) furan in 450 μl of anhydrous dimethyl sulfoxide. 401.9 mg (77.5%) of the title compound are obtained. NMR spectrum (CDC1a, b): 6.85-7.5 (multiplet, 7H, aromatic), 7.5-8.05 (multiplet, 2H, aromatic), 5.25-6.75 (multiplet, 4H , olefinic protons), 3.92 (singlet, 3N, OCH).
    In a similar way receive:
    methyl ester 2,3,4,17,18,19,20 heptanor-1, 5-inter-m-phenylene-16- (mtrifluoromethylphenoxy) -RSH Ob, NMR (CEDSEa, b): 7.1-7.5 (multiplet, aromatic protons), 7.5-8.05 (multiplet, 3N, aromatic protons);
    2,3,4-trinor-1,5inter-m-phenylene-20-methyl-PCP, 2 methyl ester, NMR (VTS, b): 0.89 (triplet, 3N, CH); 3.90 (singlet, ZN-OCHs); 5.23-6.7 (multiplet, 4H, olefinic protons); 7.2-7.55 (multiplet, 2H, aromatic protons), 7.5-8.05 (multiplet, 2H, aromatic protons), Rf 0.34 (benzene; dioxane; acetic acid 20: 10: 1);
    2,3,4-trinor-1,5- methyl ester. inter-m-phenylene-20-ethyl-PCP, Rf 0.35 (benzene; dioxane; acetic acid 20: 10: 1).
    Example 3. Methyl ether 2,3,4,18.19.20-hexanor-1,5-inter-phenylene-11, 15-bis-tetrahydropyranyloxy-16-acetylamino-17-phenyl-PCP-sat.
    The operation is carried out as described in example 1 with the difference that a solution of 1.37 g (2.59 mmol) of 3.3a ,, 5.6,
    6q, ft -hex hydro-2-hydroxy-4u-3-to-tetrahydropyranylNoloki) -4-pnetaMIDo-5phenyl-1 -trais-pentepyl-5 sat-tetrachydropyranyloxy-2H-cyclopentane 11a (in furan in 500 μl anhydrous dimethylsulphyraxide). g (70%) of the specified product Rf 0.05 (benzene: dioxane: acetic acid 20: 10: 1, silica gel (Merck C).
    Example 4. 2,3,4-trinor-1,5-inter-m-fensh-en-16-amino-PCP methyl ester,).
    a) They work in the manner described in Example 2 with the difference that a solution of 0.497 g (1.29 mmol) of 3.3 a, / ,, 5,6, 6a, 1-hexahydro-2-hydroxy-4- 3-hydroxy4- (tert-butoxy-carbonylamino) -trans-octenyl-5oi-hydroxy-2H-cyclopenta (c) furan in 400 μl of anhydrous dimethyl sulfoxide. 0.450 g (87%) of methyl ester is obtained.
    2,3,4-trinor-1,5-inter-m-phenylene-16 (tert-butoxycarbonylamino) -PCP2, Rf 0.31 (silica gel G, ethyl acetate:: benzene 4: 1).
    In the same way, a methyl ester of 2,3,4,17,18,19,20 heptanor-1, 5-inter-m-phenylene-16-phenyl-16- (three T-butoxycarbonylamino), Rf 0.35 (ethyl acetate : benzene 4: 1)
    methyl ether 2; 3,4,18,19.20-hexanor-1, 5-inter-m-phenylene-1b- (tert-butoxycarbonylamino) -17-phenyl-RStG2 "C Rf 0.36 (ethyl acetate: benzene 4: 1) .
    b) 0.450 g (0.87 mmol) of 2,3,4-trinor-1,5-inter-m-phenylene-16 (tert-butoxycarbonylamino) methyl ester is dissolved in 5 ml of acetic acid and 1.05 equivalent of dry is passed into the solution. hydrogen chloride gas. The end of the reaction is determined by gassing (isobutylene). The reaction mixture is then diluted with 50 ml of ethyl acetate and with vigorous stirring with
    1 N sodium hydroxide solution pH was adjusted to 8-9. The aqueous phase is separated and the organic phase is evaporated to dryness after drying with anhydrous sodium sulfate. With the product chromatographic on a column of silica gel with a mixture of isopropano: water 8: 1. The fractions with Rf 0.4 (isopropanol 7: 2) are collected and evaporated. 0.291 g of product is obtained.
    In the same way, a methyl ester of 2,3,4,17,18,19,20 heptanor-1d5-inter-m-phenylene-16-amino-1 b-phenyl-POP with .Rf 0.45 (isopropanol: water 72 ); methyl ester 2,3,4,18.19,20-gek Sanor-1,5-inter-m-phenylene-16-amino1 7-phenyl-PCP2 ot (isopropanol 7: 2) .. Example 5. Methyl ether 2,3 , 4-trinor-1,5-inter-m-phenylene-16 acetylamino-PCP2o; . 2.5 g (5.92 mol) of 16-amino-2,3,4-trinor-1,5-inter-m-phenylene-PCP o6- methyl ester is dissolved in 3 m anhydrous pyridine. The solution is cooled to O C and mixed with dropwise with 0.98 g (0.79 ml; 12.5 mmol) of acetyl chloride. The reaction mixture was stirred for 30 minutes and then diluted with 50 ml of ethyl acetate. The organic phase is washed with 10 m of 1N hydrochloric acid, dried with anhydrous magnesium sulfate and, after filtration, the solvent is evaporated under reduced pressure. 2.36 g (86%) of 2,3,4-trinor-1,5-ethyl-p-phenylen-16-acetylamino-PGPoo (, Rf 0.7 (isopropanol: water 7: 2) are obtained. In the same way receive: 2,3,4-trinor-1,5inter-m-phenylene-16-benzoyl-amino-PGFJ Rf 0.67 methyl ester (isopropanol: water 7: 2); 2,3,4-trinor-1 methyl ester , 5m-phenylen-16-tosylamino-PGEJOiRf 0.61 (isopropanol: water 7: 2). Example 6. Methyl ether 2,3,4,17,18,19,20-heptanop-1,5-inter-m -phenylene-5-yod-16-phenoxy-PGI. 355 g (0.81 mmol) of methyl ether 2,3,4,17, 18,19,20-heptanor-1,5 inter-m-phenylene-16- phenoxy-PGF2 oi is dissolved in 5 ml of anhydrous dichloromethane. To the solution, 4.05 ml of 1 M solution of bicarbonate three. The biphasic mixture was stirred vigorously at O and G at this temperature for 15 minutes was added 16.4 m (1.62 mmol) of 0.0976 M iodine solution in dichloromethane. The addition-finished 50
    The mixture was stirred at room temperature for 3 hours and then a 3% aqueous solution of sodium thiosulfate was added until decolorized. The aqueous phase is extracted (3x50 ml) with ether and then with 20 ml of ethyl acetate. The combined organic phases are dried with sodium sulfate, filtered and the solvent
    acetate. The organic phase is washed (2 x 10 ml) with 1N oxalic acid, dried with anhydrous magnesium sulfate and, after filtration, the solvent is distilled off under reduced pressure.
    The resulting crude methyl 2,3,4-trinor-1,5-inter-m-phenylene-16 methyl ester (triphophatacetamide) -PGF2 is dissolved and DISCONNECTED under reduced pressure. 530 mg of crude product is obtained. The product is chromatographed on a 100 g filled silica gel (Merck Att. No. 7734, particle size 0.03-0.2 mm) with ethyl acetate. The corresponding Rf 0.49 and 0.47 fractions are combined and the solvent is distilled off under reduced pressure. The weight of both fractions is 493 mg (87%). In the same way, the following methyl ester is obtained: 2,3,4,17,18,19,20 heptanor-1, 5-inter-m-phenylene-5-iod 16- (3-tri-fluoropropylmethylphenoxy) -PGI, Rf 0.51 and 0, 48 (etxtacetate); 2,3,4-trinor-1,5-ethyl-p-phenylen-5-yod-16-acetylamino-PGG methyl ester, Rf 0.6 (isopropanol: water 7: 2); 2,3,4-trinor-1,5inter-m-phenylene-5-iodo-16-benzoylamino-PGI Rf 0.63 methyl ester (isopropanol: water 7: 2); 2,3,4-trinor-1,5inter-m-phenylene-5-iodo-16-toside methyl ester Ho-PGI Rf 0.56 (isopropanol: bo 7: 2); 2.3,4-trinor-1,5-inter-m-phenylene 5-yod-2b-methyl-PGI Rf 0.43 and 0.40 (ethyl acetate); 2,3,4-trinor-1,5-syn-m-phenylenyl 5-yod-20-ethyl-PGI Rf 0.43 and 0.41 methyl ester (ethyl acetate); 2,3,4,17,18,19,20 heptanor-1, 5, -inter-m-phenylene-5-iod11, 15-diacetoxy-1 b-phenoxy-PGI, Rf 0.7 and 0.72 methyl ester ether (benzene: ethyl acetate 1: 1). Example 7. 2,3,4-Trinor-1,5-inter-m-phenylene 5-bromo-16-amino-PGI methyl ester. 460 mg (1.1 mmol) of 2,3,4-trinor-1,5-inter-m-phenylene-16-amino-PGP2c methyl ester (, dissolved in 3 ml of anhydrous triethylamine. The solution is cooled before and then mixed with 160 µl (1.15 mmol) of anhydrous trifluoroacetic acid. The reaction mixture is stirred at 0 ° C for 5 hours and then diluted with 50 ml of ethyl in anhydrous mixture of chloroform and tetrahydrofuran (1: 1). The solution is cooled to (cooling mixture of dry ice with acetone) and stirred under protective gas. After the addition of 215.4 mg (1.21 mmol) of solid N-bromosuccinimide, the reaction mixture is stirred for another 10 minutes after -78 ° C, then the cooling is removed. After the temperature of the reaction mixture rises to room temperature, it is stirred at this temperature for 30 minutes and then the reaction mixture is diluted with 50 ml of chloroform and washed (3 x 20 ml) with water. The organic phase is dried with sodium sulfate and filtration, the solvent was distilled off under reduced pressure. 680 mg of 2,3,4-trinor-1 methyl ester, 5-inter-m-phenylene-5-bromo-16 were obtained in the residue.
    (trifluoroacetamido) -PC1 Rf 0.35 (ethyl acetate: benzene 3: 1).
    . The crude product is stirred for 1 hour with a 0.03 M solution of potassium bicarbonate in a mixture of water: methanol 95: 5. The aqueous phase is then extracted (5x5 ml) with ethyl acetate, the combined organic phases are dried with potassium carbonate, filtered and then with reduced
    -pressure evaporated. 395 mg (72%) of the product are obtained, Rf 0.45 (isopropanol: water 7: 2).
    In the same way receive:
    methyl ester 2,3,4,17 18,19,20 heptanor-1, 5-inter-m-phenylene-5-bromo-16-amino-16-phenyl-PC1J Rf 0.49 (ispropanol: water 7: 2);
    2,3,4,18,19,20-hecnor-1, 5-inter-m-phenylene-5-bromo-16-amno-17-phenyl-PC1 methyl ester) Rf 0.47 (isopropanol: water 7: 2).
    Example 8. Methyl ether 2, 4,17,18,19,20-heptanor-1,5-inter-phenylen-16-phenoxy-PGIn.
    To 230.4 mg (0.40 mmol) of ethyl ester 2,3,4,17, .18,19,20-heptanor-1,5inter-m-phenylene-5-iodine-16-phenoxy PGIf add 2 ml of distilled 1,5-diazabicyclo- (4,3,0) non-5-ene. The mixture is stirred for 1 hour at 50 ° C, then diluted with 50 ml of ether and the organic phase is washed (2 x 20 ml) with water. Then dried with sulphate; sodium and distilled ether under reduced pressure. Get 210 mg of crude product.
    The crude product is chromatographed on a filled 60 g silica gel (Merck Art. No. 7734, grain size 0.030, 2 mm) column of ether: acetone mixture 3: 1. The fractions with Rf 0.49 and 0.51 are collected and the solvent is evaporated, yielding 152.1 mg (85.47) of product.
    Thin layer chromatography: Z-isomer has Rf 0.51, B-isomer -0.49.
    In the same way, the following compounds were prepared:
    2,3,4,17,18,19,20 heptanor-1 methyl ester, 5-inter-m-phenylene-16- (3 trifluoromethylphenoxy) -PC12 Rf 0.51 and 0.53 (ethyl acetate);
    2,3,4, -trinor-1,5icter-m-phenylene-1b-amino-PC methyl ester Rf 0.45 (isopropanol: water 7: 3);
    2,3,4-trinor-1,5inter-m-phenylene-1b-acetamido-PGI Rf 0.70; (isopropanol: water 8: 3);
    2,3,4-trinol-1,5inter-m-phenylene-16-benzoylamino-PC12 Rf 0.74 methyl ester; (isopropanol: water 7: 3);
    2,3,4,17,18,19,20 heptanor-1 methyl ester, 5-inter-m-phenylene-16g-amino-16-phenyl-PC12 Rf 0.49 (isopropanol: water 7: 3);
    2,3,4,18,19,20hexanor-1, 5-inter-m-phenyl-16-amino-17-phenyl-PC12 Rf 0.53 methyl ester (isopropanol: water 7: 3),
    Example 9. The sodium salt of 5 (g) -2,3,4,17,18,19,20-heptanor-1,5inter-m-phenylene-1b-phenoxy-RS.
    338.7 mg (0.78 mmol) of methyl ester 5 (Z) -2,3,4, 19,20-heptanor-1-, 5-inter-m-phenylene-PC12 dissolved in 2 ml of methanol, K 1.86 ml (0.93 mmol) of 0.5 M methanolic sodium hydroxide solution is added to the solution at room temperature. The mixture was stirred for 6 hours at room temperature, then the methanol was distilled off under reduced pressure. The solid residue is suspended in petroleum ether and then decanted. 340.4 mg (98%) of product Rf 0.43 are obtained (benzene dioxane: acetic acid 20: 10: 1). NMR (deuteromethanol, 5.32 (broad singlet, 1H, protons in the 5-position); 5.45-5.77 (multiplet, 2H, olefinic protons); 6.9-7.5 (multiplet, 6H, aromatic protons ), 7.5-8.15 (multiplet, 3N, aromatic protons).
    In the same way, the following compounds are prepared:
    sodium salt 5 (e) -2,3,4,17,18, 19,20-heptan org-1,5-inter-m-fensh-en-6-phenoxy-PGl. JRf 0.41; (benzene: whether
    权利要求:
    Claims (3)
    [1]
    1. METHOD FOR PRODUCING 2,3,4-TRINOR-M-INTER-PHENIPENPROSTAGLANDINE DERIVATIVES of General Formula I where R ^ ~ Rjj have the indicated meanings, are reacted with phosphorane obtained from the phosphonium salt of the general formula (III)
    SU <. " 1138020 where is alkyl with 1-4 carbon atoms, an alkali metal cation or primary, secondary, tertiary or quaternary ammonium cation; independently of each other. are hydrogen, alkanoyl with 1-4 carbon atoms, tetrahydropyranyl, this is where Ph is phenyl;
    X is a monovalent anion, under the action of a strong base in a dipolar aprotic solvent, the obtained derivative of the general form 1138020 where R | - hydrogen;
    R ^ - R ^ ~ have the indicated meanings, are converted to the ester derivative of the formula (IV), where is alkyl 'with 1-4 carbon atoms, and when Z is an unsubstituted amino group, acylate to obtain a compound of the formula (IV), where Z has the other indicated values, and the resulting compound of formula (IV) is treated with compound *, EX. where X '. is halogen, and E is a halo, gene or N-succinimide group, in an organic solvent not miscible with water or in a two-phase system obtained from it and water, if necessary in the presence of an acid acceptor, the obtained halogenated PGl derivative of the general formula ( V) where they have the indicated meanings, a Z has other meanings than hydrogen, is treated with a base followed by either hydrolysis of a compound of formula (I), where Rj is alkyl, into a compound of formula (I), where R ^ is hydrogen, or by salt formation of a compound of formula I where R | is hydrogen, in the compound formulas are (I), wherein - said cation or deacylation of compounds of formula (I), wherein Z - alkanoylamino group, into a compound of formula (I), wherein Z - unsubstituted amino group.
    [2]
    2. The method according to π. 1, with the fact that sodium bicarbonate is used as an acid acceptor in the treatment of a compound of formula (IV) with compound EX.
    [3]
    3. The method according to p. 1, characterized in that the halogenated PGlg derivative of the general formula (V) is treated with 1,5-diazabicyclo (4.3.0) non-5-ene.
    12
    类似技术:
    公开号 | 公开日 | 专利标题
    EP1254883B1|2009-09-23|Process for producing substituted 1,1,1-trifluoro-3-butene-2-ones
    DK158672B|1990-07-02|METHOD FOR PREPARING 3-SUBSTITUTED-METHYL-7-METHOXY-7BETA- | -3-CEPHEM-4-CARBOXYLY ACID AND ALKALIMETAL SALTS.
    SU921465A3|1982-04-15|Method of producing prostane derivatives of salts thereof
    KR20130018809A|2013-02-25|Process for preparing sulfonamido-benzofuran derivatives
    BG97471A|1994-03-24|Process for the preparation of 13,14-dihydro-15|-17-phenyl-18,19,20-trinor-pgf2ó esters
    SU1138020A3|1985-01-30|Method of obtaining derivatives of 2,3,4-trinor-m-inter-phenylprostaglandine
    US4143046A|1979-03-06|Carbon and oxygen analogs of penicillin
    Bukownik et al.1988|Synthetic receptors. 3, 6-Anhydro-7-benzenesulfonamido-1, 7-dideoxy-4, 5-O-isopropylidene-D-altro-hept-1-ynitol: A useful component for the preparation of chiral water-soluble cyclophanes based on carbohydrate precursors
    US4282149A|1981-08-04|Carbon and oxygen analogs of penicillin
    SU1277897A3|1986-12-15|Method of producing 1,1-dioxo-6-brom| penicillanoyloxymethyl ethers of 6-|penicillanic acid
    JP2991348B2|1999-12-20|7- | oxy-9a-methoxymitosan and its production and use
    SU955861A3|1982-08-30|Process for producing derivatives of streptovaricin
    US4107181A|1978-08-15|Useful prostaglandin intermediates
    JPWO2018220888A1|2020-05-07|PGE1 core block derivative and method for producing the same
    Barili et al.1987|Alkaline and enzymatic hydrolysis of isobutyl 3, 4-anhydro-2, 6-dideoxy-DL-hexopyranosides. Preparation of enantiomeric boivinopyranosides through a highly efficient kinetic resolution
    Turkenburg et al.1982|SN2 substitution with inversion at a cyclopropyl carbon atom: formation of 9-oxatetracyclo [6.2. 1.01, 6.06, 10] undecane
    FI71562C|1987-01-19|FOERFARANDE FOER FRAMSTAELLNING AV 6- - SUBSTITUERADE PENICILLANSYRADERIVAT OCH SAOSOM MELLANPRODUKTER ANVAENDBARA 6-PERFLUORALKYLSULFONYLOXIPENICILLANSYRADERIVAT.
    EP0135683B1|1987-07-22|Method for production of cephalosporin compounds
    US4191823A|1980-03-04|Process for the preparation of oxaprostaglandin intermediates
    US5084578A|1992-01-28|Process for producing 1,3-substituted tetrahydro-1H-thieno-[3,4-D]-imidazol-2|-on-4-ylidene pentanoic acid ester
    RU1830070C|1993-07-23|Method for producing allyl-7 -phenoxyacetylamino-3-methyl-1-carba |-3-cephem-4-carboxylate
    US4176122A|1979-11-27|Process for the preparation of bicyclic enone compounds
    PL126831B1|1983-09-30|Method of obtaining n-thiocraboxyanhydride of l-asparaginic acid
    Christov et al.2002|Alkatrienyl sulfoxides and sulfones. Part II.[1]| phenyl sulfoxide-synthesis and electrophile-promoted cyclization reactions
    GB1589200A|1981-05-07|Prostaglandin derivatives
    同族专利:
    公开号 | 公开日
    DD202434A5|1983-09-14|
    CS241102B2|1986-03-13|
    CS256182A2|1985-07-16|
    EP0062902B1|1986-01-15|
    DK165882A|1982-10-15|
    GR76127B|1984-08-03|
    FI821164A0|1982-04-02|
    PL129427B1|1984-05-31|
    FI75156B|1988-01-29|
    FI75156C|1988-05-09|
    DE3268487D1|1986-02-27|
    IL65387D0|1982-05-31|
    PL235949A1|1983-01-03|
    FI821164L|1982-10-15|
    US4451483A|1984-05-29|
    AT381494B|1986-10-27|
    EP0062902A1|1982-10-20|
    ATA139282A|1986-03-15|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    BE795200A|1972-05-10|1973-08-09|Ciba Geigy|NEW OXABICYCLOOCTANES AND THEIR PREPARATION METHODS|
    HU179001B|1978-05-29|1982-08-28|Chinoin Gyogyszer Es Vegyeszet|Process for preparing 5-halo-6,9alpha-oxido-prostaglandin derivatives|
    US4312810A|1978-11-22|1982-01-26|The Upjohn Company|2,5-Inter-o-phenylene-3,4-dinor-5,9α-epoxy-9-deoxy-PGF1 compounds|
    DE3029984C2|1980-08-08|1983-12-15|Grünenthal GmbH, 5190 Stolberg|2-Oxabicyclo [3.3.0] octane derivatives and medicinal products containing them|IL67332A|1981-12-01|1985-12-31|Chinoin Gyogyszer Es Vegyeszet|Inter-m-phenylene-prostacyclin analogues,process for the preparation thereof and pharmaceutical compositions containing them|
    HU188559B|1981-12-01|1986-04-28|Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu|Process for preparing new inter-m-phenylene-prostacyclin derivatives|
    HU190007B|1982-05-06|1986-08-28|Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu|Process for producing new aromatic prostacylin analogues|
    DE3317159C2|1982-05-27|1992-02-06|Gruenenthal Gmbh, 5100 Aachen, De|
    US4474804A|1983-09-19|1984-10-02|E. R. Squibb & Sons, Inc.|7-Oxabicyclo substituted prostaglandin phenyl carboxylic acid derivatives useful as cardiovascular agents|
    DE3408699A1|1984-03-08|1985-09-12|Schering AG, 1000 Berlin und 4709 Bergkamen|NEW CARBACYCLINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS|
    US5661178A|1995-09-01|1997-08-26|Allergan|Method for effecting vasodilation with aryl prostaglandin derivatives|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    HU96281A|HU189974B|1981-04-14|1981-04-14|Process for preparing 2,3,4-trinor-m-inter-phenylidene.pgi down 2 derivatives|
    HU96481A|HU188009B|1981-04-14|1981-04-14|Process for preparing new derivatives of 2,3,4-trinor-1,5-inter-m-phenylene-pgt down 2alpha|
    HU96381A|HU188286B|1981-04-14|1981-04-14|Process for producing 2,3,4-tri-nor-m-inter-phenilidene-pgi-1 down derivatives|
    [返回顶部]